KM Research Hub

REVIEW LEDGER

论文复核台

集中查看元数据入排不确定项,以及已识别 KM 但需确认 No. at risk 的内容复核项。

论文元数据入排图像/No. at risk 复核依据
Suvemcitug plus chemotherapy in women with platinum-resistant recurrent ovarian cancer: the SCORES randomized, double-blinded, phase 3 trial.PMID 41514054 · 2026-Janeligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
[Effects of Early Enteral Nutrition After Total Gastrectomy for Gastric Cancer].PMID 42615657 · 2026needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Comparison of Modified Pectoral Nerve Block and Erector Spinae Plane Block for Postoperative Analgesia and Surgical Stress Response Following Modified Radical Mastectomy: A Prospective, Randomised, Blinded Study.PMID 42830681 · 2026needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Planning, Reporting, and Selective Disclosure of Quality-of-Life End Points in Phase III Genitourinary Cancer Trials.PMID 42663007 · 2026needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
The optimal temperature of air-heated blankets for preventing intraoperative hypothermia in patients with gynecological tumor: a randomized controlled trial.PMID 42621069 · 2026needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Function-preserving intracapsular versus superficial parotidectomy for benign parotid tumors: A randomized controlled trial.PMID 42707349 · 2026needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Characteristics and research waste of immunotherapy randomized clinical trials: a cross-sectional analysis.PMID 42676491 · 2026needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Chemoradiotherapy versus transoral laser microsurgery for early T-stage (cT1-T2) hypopharyngeal cancer: A prospective randomized pilot study.PMID 42710434 · 2026needs_review未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。pending-未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。
Analgesic Efficacy of Different Doses of Esketamine as an Adjuvant to Ropivacaine for Thoracoscopy-Guided Thoracic Paravertebral Block After Thoracoscopic Radical Resection for Lung Cancer: A Prospective Randomized Controlled Trial.PMID 42764888 · 2026needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Health-related quality of life with adjuvant immune checkpoint inhibition in renal cell carcinoma: A qualitative study of UK participants in the phase III RAMPART trial.PMID 42766600 · 2026needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Protocol of the PANEM trial: A randomized, phase III, parallel-arm, placebo-controlled, double-blind, multi-center superiority trial comparing PANcreatic EnzyMes versus placebo in adults after gastrectomy.PMID 42771661 · 2026needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Comparison of Remimazolam and Propofol for Anesthesia Management in Liver Cancer Patients Undergoing Percutaneous Radiofrequency Ablation: A Randomized Controlled Trial.PMID 42801141 · 2026needs_review未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。pending-未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。
I need it. Without it, I wouldn't have gone, and I do want to go: patient perspectives on the acceptability and appropriateness of two patient-centered interventions to improve adherence to annual lung cancer screening.PMID 42846115 · 2026needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Impact of Neoadjuvant Carboplatin in Early-Stage Triple-Negative Breast Cancer: A Pooled Analysis of the BrighTNess, Cancer and Leukemia Group B 40603 (Alliance), and GeparSixto Clinical Trials.PMID 42992319 · 2026needs_review未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。pending-未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。
Ultrasound-guided costotransverse block with systemic adjuvants for complete opioid-free breast cancer surgery: A randomized controlled trial.PMID 43048737 · 2026needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Immunohistochemistry for c-MET, HLA class II, and CD68 does not show prognostic value in early-stage classic Hodgkin lymphoma patients in the EORTC-GELA H9 intergroup randomised trial.PMID 42848781 · 2026needs_review未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。pending-未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。
Long-term post-trial extension of osilodrostat therapy in selected Canadian patients with Cushing disease from the LINC 3 and LINC 4 programs.PMID 42935875 · 2026needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Intra-operative oxygen concentration could affect postoperative morbidity-results of a randomised controlled feasibility trial (PULSE Ox).PMID 42903451 · 2026needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Short course versus conventional interventional radiotherapy (brachytherapy) regimen in locally advanced cervical cancer: A randomized clinical trial.PMID 42722513 · 2026needs_review未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。pending-未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。
Estimands for Randomized Discontinuation Designs in Oncology.PMID 42968527 · 2026needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial.PMID 41287969 · 2026eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Preoperative Chemoradiotherapy versus Chemotherapy for Locally Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma: A Phase III Randomized Controlled Trial from China.PMID 41625476 · 2026eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Vebreltinib for Previously Treated Astrocytoma, IDH-Mutant, Grade 4, and Glioblastoma, IDH Wild-Type with PTPRZ1-MET Fusion Gene: A Multicenter, Phase III Randomized, Open-Label Trial.PMID 41821581 · 2026eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 Study.PMID 42282892 · 2026eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Early divergence of treatment response trajectories to adalimumab or its biosimilar in active ankylosing spondylitis: consensus clustering analysis of a randomized controlled trial.PMID 42416060 · 2026needs_reviewThe study is a randomized Phase III trial of a drug (adalimumab or its biosimilar) in humans with a malignant-neoplasm-adjacent mesh term (Spondylitis, Ankylosing) but is not an oncology study. It also does not report a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR).pending-The study is a randomized Phase III trial of a drug (adalimumab or its biosimilar) in humans with a malignant-neoplasm-adjacent mesh term (Spondylitis, Ankylosing) but is not an oncology study. It also does not report a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR).
Intergroup randomized phase III study of adjuvant FOLFIRI, FOLFOX, or 5-FU/leucovorin for stage II/III rectal cancer: ECOG-ACRIN E3201.PMID 41397917 · 2025-Dec-27eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial.PMID 41037766 · 2025-Dec-20eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
LEF1 intragenic deletion induces a dominant-negative isoform and unveils a Wnt/β-catenin vulnerability in T-ALL.PMID 40857670 · 2025-Dec-18needs_reviewThe study analyzes genetic alterations (LEF1) in T-ALL cohorts from completed trials and explores a biological mechanism. While it mentions enhancing chemosensitivity as a potential strategy, it does not present a drug intervention with a time-to-event efficacy endpoint. Therefore, it does not meet the criteria for a drug-intervention randomized trial with a primary/key secondary time-to-event efficacy endpoint.pending-The study analyzes genetic alterations (LEF1) in T-ALL cohorts from completed trials and explores a biological mechanism. While it mentions enhancing chemosensitivity as a potential strategy, it does not present a drug intervention with a time-to-event efficacy endpoint. Therefore, it does not meet the criteria for a drug-intervention randomized trial with a primary/key secondary time-to-event efficacy endpoint.
Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial.PMID 40991848 · 2025-Dec-18eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer.PMID 41124204 · 2025-Dec-18eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Prognostic Significance and Predictive Value of Circulating Tumor Cells in Invasive Lobular Breast Carcinoma-An Exploratory Analysis of the STIC CTC Trial.PMID 41020765 · 2025-Dec-15eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer.PMID 41124210 · 2025-Dec-11eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.PMID 40991874 · 2025-Dec-10eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma.PMID 41187298 · 2025-Dec-10eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009.PMID 41213101 · 2025-Dec-10eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Patient-reported outcomes with paclitaxel and ramucirumab switch maintenance in advanced gastroesophageal cancer: A secondary endpoint of the ARMANI phase 3 trial.PMID 41138601 · 2025-Dec-09eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
First-line pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: Health-related quality of life from the randomized phase III KEYNOTE-859 trial.PMID 41175805 · 2025-Dec-09eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial.PMID 41072417 · 2025-Dec-08eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma.PMID 41345095 · 2025-Dec-04eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations.PMID 41339316 · 2025-Dec-03eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant Prostate Cancer: Results from the ProBio Platform Trial.PMID 40263079 · 2025-Deceligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Dostarlimab and niraparib in primary advanced ovarian cancer.PMID 40461381 · 2025-Deceligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinoma.PMID 40885527 · 2025-Deceligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma.PMID 40885529 · 2025-Deceligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients.PMID 40885530 · 2025-Deceligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Randomized phase III trial of adjuvant radiation versus chemoradiation in intermediate-risk, early-stage cervical cancer following radical hysterectomy and lymphadenectomy: results from NRG Oncology/GOG-263/KGOG 1008.PMID 40947016 · 2025-Deceligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Retifanlimab versus placebo in combination with platinum-based chemotherapy in patients with first-line non-squamous or squamous metastatic non-small-cell lung cancer (POD1UM-304): a phase 3, multiregional, placebo-controlled, double-blind, randomised study.PMID 40983066 · 2025-Deceligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Addressing Uneven Treatment Discontinuation Rate in the Chemotherapy Arm of the EV-302 Phase 3 Randomized Clinical Trial: Implications for Outcome Interpretation.PMID 41046201 · 2025-Deceligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Dose de-escalation of elective neck irradiation in head and neck cancer: A secondary analysis of acute toxicity findings from the randomized controlled UPGRADE-RT trial.PMID 41057084 · 2025-Decneeds_reviewThe record is a secondary analysis of a Phase III randomized trial in head and neck cancer, but it reports only acute toxicity endpoints (dysphagia, mucositis), not the required survival, progression, recurrence, death, or time-to-event efficacy outcomes. Therefore, eligibility cannot be established.pending-The record is a secondary analysis of a Phase III randomized trial in head and neck cancer, but it reports only acute toxicity endpoints (dysphagia, mucositis), not the required survival, progression, recurrence, death, or time-to-event efficacy outcomes. Therefore, eligibility cannot be established.
Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.PMID 41057655 · 2025-Deceligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。